Oxaliplatin Injection |
Eloxatin |
Clinical Trial: Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-small Cell Lung Cancer (NSCLC)
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC).
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Drug: Gemcitabine/Oxaliplatin (GEMOX) Drug: Carboplatin/Paclitaxel (CP) | Phase III |
MedlinePlus related topics: Cancer; Lung Cancer
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase III Randomized Trial of Gemcitabine/Oxaliplatin (GEMOX) versus Carboplatin/Paclitaxel (CP) as First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Expected Total Enrollment: 480
Study start: March 2004
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Newly diagnosed, Stage IIIb or IV NSCLC, chemo or other systemic therapy naive
- One (1) unidimensionally measurable lesion
- ECOG Performance Status of 0 or 1, no peripheral neuropathy >Grade 1
- Patients with clinically stable brain metastases on a stable dose of (or no longer requiring) dexamethasone at registration will be eligible. Patients who have received cranial radiation for brain metastases must be at least 4 weeks from last radiation treatment.
- Recovery in full from any previous surgical procedure
- No history of an acute cardiac or CNS event within 6 months of entry or current clinical evidence of congestive heart failure or non-stable coronary artery disease
Exclusion Criteria:
- Hypersensitivity to any of the 4 study drugs
- Concurrent immunotherapy or participation in any investigational drug study within 4 weeks
- Serious uncontrolled intercurrent medical or psychiatric illness and organ allograft
- History of other malignancy within the last 5 years (except for squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix, or superficial transitional cell carcinoma of the bladder)
- Patient is a pregnant or lactating female
Location and Contact Information
Sharon Pritchard 214-584-3217 sharon.pritchard@usoncology.com
Alabama
Birmingham Hematology and Oncology Associates, Birmingham, Alabama, 35235, United States; Recruiting
Birmingham Hematology and Oncology Associates, LLC, Birmingham, Alabama, 35235, United States; Recruiting
Arizona
Arizona Oncology Associates - Hematology Oncology Physicians, Tucson, Arizona, 85704, United States; Recruiting
Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, 86336, United States; Recruiting
Hematology Oncology Associates, Phoenix, Arizona, 85012, United States; Recruiting
Colorado
Rocky Mountain Cancer Centers, Denver, Colorado, 80218, United States; Recruiting
Florida
South Florida Oncology & Hematology Consultants, Plantation, Florida, 33324, United States; Recruiting
Cancer Centers of Florida, P.A., Ocoee, Florida, 34761, United States; Recruiting
Ocala Oncology Center, Ocala, Florida, 34474, United States; Recruiting
Florida Cancer Institute, New Port Richey, Florida, 34652, United States; Recruiting
Illinois
Hematology Oncology Associates of Illinois, Skokie, Illinois, 60077, United States; Recruiting
Northwest Medical Specialists, PC, Niles, Illinois, 60714, United States; Recruiting
Hematology Oncology Associates of Illinois, Chicago, Illinois, 60611, United States; Recruiting
Indiana
Central Indiana Cancer Centers, Indianapolis, Indiana, 46227, United States; Recruiting
Iowa
Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa, 52403, United States; Recruiting
Kansas
Kansas City Oncology and Hematology Group, Overland Park, Kansas, 66210, United States; Recruiting
Maryland
Maryland Oncology Hematology, P.A., Columbia, Maryland, 21044, United States; Recruiting
Massachusetts
Berkshire Hematology Oncology, PC, Pittsfield, Massachusetts, 01201, United States; Recruiting
Minnesota
Minnesota Oncology Hematology, Minneapolis, Minnesota, 55404, United States; Recruiting
Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, 55404, United States; Recruiting
Missouri
Arch Medical Services, Inc., St. Louis, Missouri, 63141, United States; Recruiting
Missouri Cancer Associates, Columbia, Missouri, 65201, United States; Recruiting
Nevada
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89109, United States; Recruiting
New Mexico
New Mexico Cancer Care Associates, Santa Fe, New Mexico, 87505, United States; Recruiting
New York
New York Oncology Hematology, Latham, New York, 12110, United States; Recruiting
New York Oncology Hematology, P.C., Albany, New York, 12208, United States; Recruiting
Interlakes Oncology & Hematology, P.C., Rochester, New York, 14623, United States; Recruiting
New York Oncology Hematology, P.C., Rexford, New York, 12148, United States; Recruiting
North Carolina
Raleigh Hematology Oncology Clinic, Cary, North Carolina, 27511, United States; Recruiting
Piedmont Hematology Oncology Associates, PLLC., Winston Salem, North Carolina, 27103, United States; Recruiting
Ohio
Dayton Oncology & Hematology, P.A., Kettering, Ohio, 45409, United States; Recruiting
Oklahoma
Cancer Care Associates, Tulsa, Oklahoma, 74136-1902, United States; Recruiting
Cancer Care Associates, Oklahoma City, Oklahoma, 73120, United States; Recruiting
Oregon
Willamette Valley Cancer Center, Eugene, Oregon, 97401, United States; Recruiting
South Carolina
Cancer Centers of the Carolinas, Seneca, South Carolina, 29672, United States; Recruiting
Texas
The Texas Cancer Center, Dallas, Texas, 75237, United States; Recruiting
Texas Oncology, P.A., Dallas, Texas, 75246, United States; Recruiting
Texas Oncology, P.A., Dallas, Texas, 75231, United States; Recruiting
Texas Cancer Center at Medical City, Dallas, Texas, 75230-2510, United States; Recruiting
Texas Oncology, P.A., Bedford, Texas, 76022, United States; Recruiting
Mamie McFaddin Ward Cancer Center, Beaumont, Texas, 77702-1449, United States; Recruiting
Texas Oncology Cancer Center, Austin, Texas, 78731, United States; Recruiting
Texas Oncology, P.A., Arlington, Texas, 76012, United States; Recruiting
Texas Cancer Center - Abilene, Abilene, Texas, 79606, United States; Recruiting
Texas Cancer Center of Mesquite, Mesquite, Texas, 75150, United States; Recruiting
South Texas Cancer Center - McAllen, McAllen, Texas, 78503-1298, United States; Recruiting
Longview Cancer Center, Longview, Texas, 75601, United States; Recruiting
Lake Vista Cancer Center, Lewisville, Texas, 75067, United States; Recruiting
Texas Oncology, P.A., Irving, Texas, 75061-2244, United States; Recruiting
Texas Oncology, P.A., Houston, Texas, 77024, United States; Recruiting
Texas Oncology, P.A., Garland, Texas, 75042-5788, United States; Recruiting
Texas Oncology, P.A., Fort Worth, Texas, 76104, United States; Recruiting
El Paso Cancer Treatment Ctr-East, El Paso, Texas, 79915, United States; Recruiting
Texas Cancer Center - Denton, Denton, Texas, 76210, United States; Recruiting
Deke Slayton Cancer Center, Webster, Texas, 77598, United States; Recruiting
Waco Cancer Care and Research Center, Waco, Texas, 76712, United States; Recruiting
Tyler Cancer Center, Tyler, Texas, 75702, United States; Recruiting
Texas Cancer Center - Sherman, Sherman, Texas, 75090-0504, United States; Recruiting
San Antonio Tumor and Blood Clinic, Fredericksburg, Texas, 78624, United States; Recruiting
Hematology Oncology Associates of South Texas, San Antonio, Texas, 78229, United States; Recruiting
Paris Regional Cancer Center, Paris, Texas, 75460, United States; Recruiting
West Texas Cancer Center, Odessa, Texas, 79761, United States; Recruiting
Allison Cancer Center, Midland, Texas, 79701-5946, United States; Recruiting
Virginia
Oncology & Hematology Associates of Southwest Virginia, Inc., Salem, Virginia, 24153, United States; Recruiting
Virginia Oncology Associates, Norfolk, Virginia, 23502, United States; Recruiting
Fairfax Northern Virginia Hematology Oncology, PC, Fairfax, Virginia, 22031, United States; Recruiting
Washington
Northwest Cancer Specialists, P.C., Vancouver, Washington, 98684, United States; Recruiting
Cancer Care Northwest, Spokane, Washington, 99218, United States; Recruiting
Puget Sound Cancer Centers, Seattle, Washington, 98133, United States; Recruiting
Puget Sound Cancer Centers, Edmonds, Washington, 98026, United States; Recruiting
More Information
Record last reviewed: July 2004
Last Updated: October 13, 2004
Record first received: July 13, 2004
ClinicalTrials.gov Identifier: NCT00087802
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Eloxatin (Drug Digest)
- Oxaliplatin Injection (Drug Digest)

Not Signed In -


